预约演示
更新于：2026-06-22
Soquelitinib
索奎替尼
更新于：2026-06-22
概要
基本信息
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床1/2期 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C25H30N4O4S2 |
InChIKeyKNCWSXRTKLTULH-MRXNPFEDSA-N |
CAS号2226636-04-8 |
关联
7
项与 索奎替尼 相关的临床试验NCT07441395
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
ChiCTR2500110450
A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled, Dose Escalation, Followed by a Phase 2 Extension Clinical Study Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor CPI-818 in Participants with Moderate to Severe Atopic Dermatitis
NCT06730126
A Phase 2a Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
100 项与 索奎替尼 相关的临床结果
登录后查看更多信息
100 项与 索奎替尼 相关的转化医学
登录后查看更多信息
100 项与 索奎替尼 相关的专利（医药）
登录后查看更多信息
18
项与 索奎替尼 相关的文献（医药）2026-02-01CELLULAR SIGNALLING
Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling
Article
作者: Puterbaugh, Ryan Z ; Ro, Timothy ; Callahan, Aurora ; Su, Xiaolei ; Salomon, Arthur R ; Zhang, Xinyan
Although chimeric antigen receptor (CAR) T cell therapy has revolutionised individualised cancer therapies for relapsed/refractory lymphomas, low long-term retention due to basal signalling (antigen-independent activation in the absence of cognate antigen) and off-target toxicity limit the broad applicability of CAR-T products. During CAR development, researchers use model systems, like Jurkat T cells (Jurkats), to screen intracellular signalling arrangements based on their ability to activate (e.g., CD69 expression) and withstand repeated antigen encounters. Although Jurkats are standard for CAR screening, the mapping of CAR generations to Jurkat-specific pTyr networks relative to key TCR nodes and CD69 readouts is not well defined, blurring how hierarchical signalling drives activation. Here, we investigated how costimulation influenced tyrosine phosphorylation cascades using LC-MS/MS based phosphotyrosine (pY) proteomics and CD69 expression in the presence of small molecule inhibitors of key TCR signalling regulators. We found that including TCRζ (CD3ζ; gene CD247) in first (ζ-CAR), second (28ζ-CAR and BBζ-CAR), and third (28BBζ-CAR) generation CARs largely determined pY signalling, irrespective of costimulation. Further, we showed that the phosphatase activity of PTPN22 and SHP-1 were largely negligible for activation of CARs, but indiscriminate inhibition of phosphatases using pervanadate (PV) selectively activated BBζ-CARs without antigen encounter. Finally, we found that selective, partial inhibition of Itk using Soquelitinib reduced basal CD69 expression in CAR-Jurkat cells while maintaining their ability to activate in response to antigen. These data suggest that TCRζ determines the pY signalling profile and that Itk drives basal activation of CD19-CAR Jurkats, which may impact evaluation of new CAR designs in CAR-Jurkat screens.
2025-01-01ADDICTION
Tailored text‐messaging versus standard Quitline telephone counselling for smoking cessation among people who smoke from a low‐socio‐economic status background in Australia: A study protocol for a non‐inferiority randomized controlled trial (The Quit By Phone Study)
Article
作者: Howard, Bridget C. ; Thomas, Dennis ; Barker, Daniel ; Naughton, Felix ; Anderson, Jack ; Whittaker, Robyn ; McRobbie, Hayden ; West, Robert ; Brown, Jamie ; Donnelly, Sorcha ; Stockings, Emily ; Shakeshaft, Anthony ; Courtney, Ryan J. ; Petrie, Dennis ; Patel, Kieran
Abstract:
Background and aims:
Signficant inequalities in tobacco smoking exist, with higher smoking rates among people from low‐socio‐economic status (low‐SES) populations. Tailored technology‐based programs for low‐SES smoking populations have the potential for high reach, but require effectiveness data from large‐scale trials. This trial among Australians who smoke from a low‐SES background will determine the effectiveness and cost‐effectiveness of tailored text‐message (TTM) support compared with standard Quitline (SQL) telephone support service.
Design, setting and participants:
This is a two‐arm, parallel group, randomized, non‐inferiority trial with allocation concealment and blinded outcome assessment in an Australian population within the greater Sydney region in New South Wales. Participants are adults who smoke daily (
n
= 1246), are interested in quitting and currently receiving a government pension or allowance, and will be recruited via advertisements.
Intervention and comparator:
Participants will be randomized (1:1 ratio) to receive either 12 months of TTM quit support or enrolment in SQL telephone support.
Measurements:
Assessments will be completed at baseline (telephone interview), within 1 month (check‐in call), at 3 months (on‐line questionnaire) and 12 months (telephone interview) post‐randomization. The primary outcome will be 6‐month continuous abstinence verified by carbon monoxide breath test at 12‐month follow‐up. The study will test whether TTM is non‐inferior to SQL by a non‐inferiority margin of 2%, i.e. the quit rate in the TTM group will be no worse than 2% less than the quit rate in the SQL group. Secondary outcomes will include self‐reported continuous and point prevalence abstinence and acceptability and cost‐effectiveness of TTM versus SQL.
Conclusion:
Should the tailored text‐message support prove non‐inferior and more cost‐effective than Quitline for this population, this will provide an opportunity for the upscaling of an effective, inexpensive and tailored quit support service. The trial findings will inform cessation treatment policy for priority populations in Australia and globally.
2024-07-23Science Signaling
The kinase ITK controls a Ca
2+
-mediated switch that balances T
H
17 and T
reg
cell differentiation
Article
作者: Anannya, Orchi ; August, Avery ; Huang, Weishan
The balance of proinflammatory T helper type 17 (T
H
17) and anti-inflammatory T regulatory (T
reg
) cells is crucial for immune homeostasis in health and disease. The differentiation of naïve CD4
+
T cells into T
H
17 and T
reg
cells depends on T cell receptor (TCR) signaling mediated, in part, by interleukin-2–inducible T cell kinase (ITK), which stimulates mitogen-activated protein kinases (MAPKs) and Ca
2+
signaling. Here, we report that, in the absence of ITK activity, naïve murine CD4
+
T cells cultured under T
H
17-inducing conditions expressed the T
reg
transcription factor Foxp3 and did not develop into T
H
17 cells. Furthermore, ITK inhibition in vivo during allergic inflammation increased the T
reg
:T
H
17 ratio in the lung. These switched Foxp3
+
T
reg
-like cells had suppressive function, and their transcriptomic profile resembled that of differentiated, induced T
reg
(iT
reg
) cells, but their chromatin accessibility profiles were intermediate between T
H
17 and iT
reg
cells. Like iT
reg
cells, switched Foxp3
+
T
reg
-like cells had reductions in the expression of genes involved in mitochondrial oxidative phosphorylation and glycolysis, in the activation of the mechanistic target of rapamycin (mTOR) signaling pathway, and in the abundance of the T
H
17 pioneer transcription factor BATF. This ITK-dependent switch between T
H
17 and T
reg
cells depended on Ca
2+
signaling but not on MAPKs. These findings suggest potential strategies for fine-tuning TCR signal strength through ITK to control the balance of T
H
17 and T
reg
cells.
163
项与 索奎替尼 相关的新闻（医药）2026-06-11
2026-06-10
2026-06-10
100 项与 索奎替尼 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 间变性大细胞淋巴瘤 | 临床3期 | 美国 | 2024-10-02 | |
| 间变性大细胞淋巴瘤 | 临床3期 | 澳大利亚 | 2024-10-02 | |
| 间变性大细胞淋巴瘤 | 临床3期 | 加拿大 | 2024-10-02 | |
| 滤泡性淋巴瘤 | 临床3期 | 美国 | 2024-10-02 | |
| 滤泡性淋巴瘤 | 临床3期 | 澳大利亚 | 2024-10-02 | |
| 滤泡性淋巴瘤 | 临床3期 | 加拿大 | 2024-10-02 | |
| 滤泡性T细胞淋巴瘤 | 临床3期 | 美国 | 2024-10-02 | |
| 滤泡性T细胞淋巴瘤 | 临床3期 | 澳大利亚 | 2024-10-02 | |
| 滤泡性T细胞淋巴瘤 | 临床3期 | 加拿大 | 2024-10-02 | |
| 免疫母细胞性淋巴结病 | 临床3期 | 美国 | 2024-10-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Company_Website 人工标引  | 临床1期 | 24 | 膚鑰鏇鹽範願憲餘壓積(選糧鏇願膚範願積夢選) = 繭觸鏇襯蓋網積鏇夢願 築襯鹽製糧齋製憲選憲 (醖鹹鏇窪鹹築鏇鹹鹹夢 ) 更多 | 积极 | 2026-01-20 | ||
Placebo | 膚鑰鏇鹽範願憲餘壓積(選糧鏇願膚範願積夢選) = 構製蓋鑰蓋醖選艱範膚 築襯鹽製糧齋製憲選憲 (醖鹹鏇窪鹹築鏇鹹鹹夢 ) 更多 | ||||||
临床1期 | 75 | 選襯壓憲簾淵製齋鹽範(願壓壓蓋廠鏇構艱鑰廠) = 鑰網蓋廠遞築淵鬱淵膚 淵鑰憲醖醖壓製鹽網觸 (顧鏇膚鹽網遞網鹽製膚 ) 更多 | 积极 | 2025-12-06 | |||
临床1期 | 48 | (cohort 1, 100 mg twice per day) | 衊願簾衊鹽積膚膚窪糧(夢鏇蓋構壓醖網願範鹽) = 繭獵膚製鑰夢衊壓淵鬱 鹹齋顧製鏇顧繭網壓窪 (簾廠範鑰願遞壓構窪廠 ) 更多 | 积极 | 2025-05-08 | ||
(cohort 2, 200 mg once per day) | 衊願簾衊鹽積膚膚窪糧(夢鏇蓋構壓醖網願範鹽) = 製鏇憲衊網淵夢選簾夢 鹹齋顧製鏇顧繭網壓窪 (簾廠範鑰願遞壓構窪廠 ) 更多 | ||||||
临床1期 | 64 | (Cohort 1) | 醖鏇淵築齋糧製襯壓鏇(網艱膚鑰構選顧鑰壓積) = 醖齋願衊襯網簾醖鹹簾 壓積範糧範網壓膚齋願 (構窪遞膚簾夢簾齋網齋 ) 更多 | 积极 | 2025-01-13 | ||
(Cohort 2) | 醖鏇淵築齋糧製襯壓鏇(網艱膚鑰構選顧鑰壓積) = 遞鬱觸繭夢願鹽選餘廠 壓積範糧範網壓膚齋願 (構窪遞膚簾夢簾齋網齋 ) 更多 | ||||||
临床1期 | 23 | 廠選醖簾繭觸鏇艱鹹網(製淵鏇襯蓋襯壓繭鏇鬱) = 糧顧獵簾觸膚艱憲齋鬱 襯壓蓋範觸鏇壓簾衊鏇 (夢製膚築淵鑰壓遞範壓 ) 更多 | 积极 | 2024-05-06 | |||
临床1期 | 36 | 淵顧繭鬱鹹繭鬱願齋醖(繭繭膚構齋壓願製淵鬱) = 繭繭選觸簾壓鬱廠襯遞 糧築構選艱餘窪艱艱艱 (衊鏇獵積廠鏇鑰鑰獵繭 ) | 积极 | 2023-12-09 | |||
(≥1 to ≤ 3 therapies) | 範鹹獵膚鬱醖繭製構膚(醖選積膚鬱衊網齋製夢) = 糧繭鬱艱積遞壓獵願醖 鏇餘鏇夢顧願醖積簾獵 (蓋選夢廠獵糧觸鹽壓繭 ) 更多 | ||||||
临床1期 | 3 | 衊艱醖齋築簾夢衊獵觸(醖淵糧簾鹹壓醖鬱壓繭) = soquelitinib induced normal CD4+ Th1 cells and CD8+ TEMRA cells and reduced CD4+ Treg cells in the tumor microenvironment in responding patients. 觸鹹鏇廠鹹餘鏇願簾願 (築鏇壓鏇獵壓窪觸簾糧 ) | 积极 | 2023-12-09 | |||
临床1期 | 43 | 齋網鹽範糧鹹膚願選願(壓願壓遞醖糧糧製遞糧) = 糧構窪夢鏇憲膚願觸獵 淵壓觸醖範鏇鬱窪夢積 (壓鬱憲鹹膚壓鑰餘構築 ) | 积极 | 2022-12-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用